Skip to main content
Contact Us
Subscribe
E-Edition
34°
Site search
Search
Menu
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
About Us
Contact Us
Advertise
Terms and Conditions
Privacy Policy
Home Delivery
Subscription Services
Place an Ad
Promote Your Event
Local Weather
News
Sports
Obits
Multimedia
Photo Galleries
Videos
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Subscribe
Best of 2024
Archives
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Arena Pharmaceuticals, Inc.
Arena Reports Fourth Quarter and Full Year 2021 Financial Results and Key Program Updates
February 23, 2022
From
Arena Pharmaceuticals, Inc.
Via
Business Wire
Tickers
ARNA
Arena Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
February 17, 2022
From
Arena Pharmaceuticals, Inc.
Via
Business Wire
Tickers
ARNA
Arena Pharmaceuticals to Release Fourth Quarter and Full-Year 2021 Financial Results and Provide Corporate Update on February 23
February 09, 2022
From
Arena Pharmaceuticals, Inc.
Via
Business Wire
Tickers
ARNA
Arena Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
January 18, 2022
From
Arena Pharmaceuticals, Inc.
Via
Business Wire
Tickers
ARNA
Arena Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
December 21, 2021
From
Arena Pharmaceuticals, Inc.
Via
Business Wire
Tickers
ARNA
Arena Pharmaceuticals Achieves Target Enrollment for Etrasimod CULTIVATE Study A
November 19, 2021
From
Arena Pharmaceuticals, Inc.
Via
Business Wire
Tickers
ARNA
Arena Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
November 16, 2021
From
Arena Pharmaceuticals, Inc.
Via
Business Wire
Tickers
ARNA
Arena Reports Third Quarter Financial Results and Key Program Updates
November 04, 2021
From
Arena Pharmaceuticals, Inc.
Via
Business Wire
Tickers
ARNA
Arena Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
October 21, 2021
From
Arena Pharmaceuticals, Inc.
Via
Business Wire
Tickers
ARNA
Arena Pharmaceuticals to Release Third Quarter 2021 Financial Results and Provide Corporate Update on November 4
October 14, 2021
From
Arena Pharmaceuticals, Inc.
Via
Business Wire
Tickers
ARNA
Arena Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
September 17, 2021
From
Arena Pharmaceuticals, Inc.
Via
Business Wire
Tickers
ARNA
Arena Pharmaceuticals to Host Virtual R&D Investor Calls and Participate in Upcoming September Investor Conferences
September 02, 2021
From
Arena Pharmaceuticals, Inc.
Via
Business Wire
Tickers
ARNA
Arena Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
August 18, 2021
From
Arena Pharmaceuticals, Inc.
Via
Business Wire
Tickers
ARNA
Arena Reports Second Quarter Financial Results and Key Program Updates
August 05, 2021
From
Arena Pharmaceuticals, Inc.
Via
Business Wire
Tickers
ARNA
Arena Pharmaceuticals to Release Second Quarter 2021 Financial Results and Provide Corporate Update on August 5
July 29, 2021
From
Arena Pharmaceuticals, Inc.
Via
Business Wire
Tickers
ARNA
Arena Pharmaceuticals and Aristea Therapeutics Establish Collaboration for Development of RIST4721 for Treatment of Serious Immune-Mediated Inflammatory Diseases
July 27, 2021
From
Arena Pharmaceuticals, Inc.
Via
Business Wire
Tickers
ARNA
Arena Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
July 22, 2021
From
Arena Pharmaceuticals, Inc.
Via
Business Wire
Tickers
ARNA
Arena Pharmaceuticals Appoints Doug Manion, M.D., F.R.C.P. (C), as Executive Vice President of Research & Development
July 19, 2021
From
Arena Pharmaceuticals, Inc.
Via
Business Wire
Tickers
ARNA
Arena Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
June 18, 2021
From
Arena Pharmaceuticals, Inc.
Via
Business Wire
Tickers
ARNA
Steven Schoch Elected to Arena Pharmaceuticals Board of Directors
June 14, 2021
From
Arena Pharmaceuticals, Inc.
Via
Business Wire
Tickers
ARNA
Arena Pharmaceuticals Announces Orphan Drug Designation for Etrasimod for the Treatment of Eosinophilic Esophagitis (EoE)
June 09, 2021
From
Arena Pharmaceuticals, Inc.
Via
Business Wire
Tickers
ARNA
Arena Pharmaceuticals Announces First Participant Randomized in Phase 2 Trial Evaluating Temanogrel in Coronary Microvascular Obstruction (cMVO)
June 08, 2021
From
Arena Pharmaceuticals, Inc.
Via
Business Wire
Tickers
ARNA
Arena Pharmaceuticals Earns "A" Rating from MSCI ESG, a Leading Rating Agency for Sustainable Investments
June 03, 2021
From
Arena Pharmaceuticals, Inc.
Via
Business Wire
Tickers
ARNA
Arena Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 19, 2021
From
Arena Pharmaceuticals, Inc.
Via
Business Wire
Tickers
ARNA
Arena Pharmaceuticals Earns Prime Status from ISS ESG, a Leading Rating Agency for Sustainable Investments
May 12, 2021
From
Arena Pharmaceuticals, Inc.
Via
Business Wire
Tickers
ARNA
Arena Pharmaceuticals to Release First Quarter 2021 Financial Results and Provide Corporate Update on May 5
April 28, 2021
From
Arena Pharmaceuticals, Inc.
Via
Business Wire
Tickers
ARNA
Arena Pharmaceuticals Presents Clinician and Patient Reported Outcomes Data from Phase 2b ADVISE Trial Evaluating Etrasimod in Adult Atopic Dermatitis During a Late-Breaking Session at American Academy of Dermatology VMX
April 23, 2021
From
Arena Pharmaceuticals, Inc.
Via
Business Wire
Tickers
ARNA
Arena Pharmaceuticals Releases Second Annual Environmental, Social and Governance (ESG) Report
April 19, 2021
From
Arena Pharmaceuticals, Inc.
Via
Business Wire
Tickers
ARNA
Arena Pharmaceuticals to Present Data from the Phase 2b ADVISE Trial During Late-Breaking Research Session at American Academy of Dermatology Virtual Meeting Experience
April 19, 2021
From
Arena Pharmaceuticals, Inc.
Via
Business Wire
Tickers
ARNA
Arena Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
April 16, 2021
From
Arena Pharmaceuticals, Inc.
Via
Business Wire
Tickers
ARNA
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.